384 related articles for article (PubMed ID: 24130102)
1. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
2. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
[TBL] [Abstract][Full Text] [Related]
4. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D
J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881
[TBL] [Abstract][Full Text] [Related]
5. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients.
Manguoğlu E; Güran S; Yamaç D; Colak T; Simşek M; Baykara M; Akaydın M; Lüleci G
Cancer Genet Cytogenet; 2010 Dec; 203(2):230-7. PubMed ID: 21156238
[TBL] [Abstract][Full Text] [Related]
6. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
[TBL] [Abstract][Full Text] [Related]
7. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
8. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
Kadouri L; Hubert A; Rotenberg Y; Hamburger T; Sagi M; Nechushtan C; Abeliovich D; Peretz T
J Med Genet; 2007 Jul; 44(7):467-71. PubMed ID: 17307836
[TBL] [Abstract][Full Text] [Related]
9. Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
Miramar MD; Calvo MT; Rodriguez A; Antón A; Lorente F; Barrio E; Herrero A; Burriel J; García de Jalón A
Breast Cancer Res Treat; 2008 Nov; 112(2):353-8. PubMed ID: 18176857
[TBL] [Abstract][Full Text] [Related]
10. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
12. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
13. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P;
Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744
[TBL] [Abstract][Full Text] [Related]
14. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
15. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
[TBL] [Abstract][Full Text] [Related]
16. Germline RAD51C mutations in ovarian cancer susceptibility.
Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families.
Gonzalez-Hormazabal P; Gutierrez-Enriquez S; Gaete D; Reyes JM; Peralta O; Waugh E; Gomez F; Margarit S; Bravo T; Blanco R; Diez O; Jara L
Breast Cancer Res Treat; 2011 Apr; 126(3):705-16. PubMed ID: 20859677
[TBL] [Abstract][Full Text] [Related]
18. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
20. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.
Pohlreich P; Zikan M; Stribrna J; Kleibl Z; Janatova M; Kotlas J; Zidovska J; Novotny J; Petruzelka L; Szabo C; Matous B
Breast Cancer Res; 2005; 7(5):R728-36. PubMed ID: 16168118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
